Denali Therapeutics Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Denali Therapeutics Inc. (DNLI), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are DNLI insiders buying or selling?
In the last 12 months, Denali Therapeutics Inc. insiders reported 0 open-market purchases ($0) and 6 sales ($1.3M) — net selling of $1.3M. Since August 2018, Trabud has recorded 237 Form 4 filings for DNLI: 0 buys ($0) and 237 sells ($470.6M).
Source: SEC EDGAR Form 4
What stands out
- No Denali Therapeutics Inc. insider made an open-market purchase in the last 12 months; the 6 reported open-market sales totaled $1.3M.
Key Statistics (August 2018 – Sep 9, 2026)
Total Form 4 filings
237
SEC EDGAR
Insider filers
11
Insider buys (0)
$0
Insider sells (237)
$470.6M
Insider sentiment
Net sellingNet insider flow of $470.6M in net selling since August 2018, and $1.3M in net selling over the last 12 months.
Recent DNLI insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Peter Scott Chin | Chief Medical Officer | Sale | 1.7K | $22.29 | $36.9K | SEC ↗ |
| Sep 4, 2026 | Nancy Thornberry | Director | Sale | 11.4K | $22.90 | $261.9K | SEC ↗ |
| Sep 3, 2026 | Alexander O. Schuth | COFO and Secretary | Sale | 2.8K | $23.44 | $64.9K | SEC ↗ |
| Aug 13, 2026 | Alexander O. Schuth | COFO and Secretary | Sale | 2.9K | $25.07 | $71.6K | SEC ↗ |
| Jan 8, 2026 | Ryan J. Watts | President and CEO | Sale | 35.2K | $16.50 | $580.8K | SEC ↗ |
| Jan 8, 2026 | Alexander O. Schuth | COFO and Secretary | Sale | 17.2K | $16.50 | $284.1K | SEC ↗ |
| Aug 15, 2025 | Alexander O. Schuth | COFO and Secretary | Sale | 2.9K | $13.58 | $39.9K | SEC ↗ |
| Aug 15, 2025 | Carole Ho | Chief Medical Officer | Sale | 3.7K | $13.81 | $51.7K | SEC ↗ |
| Jul 11, 2025 | Ryan J. Watts | President and CEO | Sale | 495.3K | $15.00 | $7.4M | SEC ↗ |
| Jan 9, 2025 | Carole Ho | Chief Medical Officer | Sale | 15.2K | $20.33 | $308.3K | SEC ↗ |
| Jan 9, 2025 | Alexander O. Schuth | COFO and Secretary | Sale | 15.2K | $20.33 | $308.3K | SEC ↗ |
| Jan 9, 2025 | Ryan J. Watts | President and CEO | Sale | 36.9K | $20.34 | $751.0K | SEC ↗ |
| Jan 9, 2025 | Steve E. Krognes | Director | Sale | 3.3K | $20.81 | $69.5K | SEC ↗ |
| Jan 3, 2025 | Steve E. Krognes | Director | Sale | 30.0K | $20.25 | $607.5K | SEC ↗ |
| Jan 3, 2025 | Vicki L Sato | Director | Sale | 3.1K | $20.91 | $64.4K | SEC ↗ |
| Nov 13, 2024 | David P Schenkein | Director | Sale | 59.4K | $32.51 | $1.9M | SEC ↗ |
| Nov 12, 2024 | Alexander O. Schuth | COFO and Secretary | Sale | 15.6K | $29.91 | $465.3K | SEC ↗ |
| Nov 12, 2024 | Vicki L Sato | Director | Sale | 1.0K | $30.00 | $30.6K | SEC ↗ |
| Nov 5, 2024 | Vicki L Sato | Director | Sale | 3.1K | $27.07 | $83.4K | SEC ↗ |
| Oct 22, 2024 | Ryan J. Watts | President and CEO | Sale | 40.0K | $27.69 | $1.1M | SEC ↗ |
| Oct 2, 2024 | Steve E. Krognes | Director | Sale | 30.0K | $29.03 | $870.9K | SEC ↗ |
| Sep 16, 2024 | Vicki L Sato | Director | Sale | 1.0K | $30.00 | $30.6K | SEC ↗ |
| Sep 4, 2024 | Vicki L Sato | Director | Sale | 3.1K | $25.00 | $77.0K | SEC ↗ |
| Aug 22, 2024 | Ryan J. Watts | President and CEO | Sale | 2.3K | $23.79 | $53.8K | SEC ↗ |
| Aug 22, 2024 | Steve E. Krognes | Director | Sale | 1.7K | $23.79 | $41.1K | SEC ↗ |
Showing the 25 most recent of 237 Form 4 filings for Denali Therapeutics Inc..
Most active DNLI insiders
- Alexander O. Schuth55 filings
- Carole Ho51 filings
- Ryan J. Watts51 filings
- Vicki L Sato28 filings
- Steve E. Krognes23 filings
Ask anything about DNLI insider activity
Use Trabud's AI agent to query Denali Therapeutics Inc.'s Form 4 history in plain English — "Show me DNLI CEO purchases this year" or compare it against any other ticker.
Open the AI agentDNLI insider trading FAQ
Are Denali Therapeutics Inc. insiders buying or selling?
In the last 12 months, Denali Therapeutics Inc. insiders reported 0 open-market purchases ($0) and 6 sales ($1.3M) — net selling of $1.3M. Since August 2018, Trabud has recorded 237 Form 4 filings for DNLI: 0 buys ($0) and 237 sells ($470.6M). Over the full record that is net selling of $470.6M.
How many insiders trade DNLI stock?
11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Denali Therapeutics Inc.. The most recent filing was accepted on Sep 9, 2026.
Where does Trabud get DNLI insider trading data?
All DNLI insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.